HUTCHMED Commences the P-III (RAPHAEL) Study of HMPL-306 for Treating Acute Myeloid Leukemia in China
Shots:
- HUTCHMED has commenced the P-III (RAPHAEL) study to assess the safety & efficacy of HMPL-306 alone for treating IDH1 and/or IDH2 mutated r/r acute myeloid leukemia (AML) patients (n=~320) in China. The first patient was dosed on May 11, 2024
- The P-III (RAPHAEL) trial followed the P-I study investigating the safety, PK/PD & efficacy of HMPL-306, the dose-escalation stage results of which were highlighted at EHA 2023. The dose expansion stage data among 50 patients, depicting favorable CRs at RP2D, will be highlighted at EHA 2024
- HMPL-306 is a dual-inhibitor targeting IDH1 and IDH2 enzymes, whose mutations are responsible for some hematological malignancies, gliomas & solid tumors, particularly AML
Ref: HUTCHMED | Image: HUTCHMED
Related News:- The NMPA Accepts HUTCHMED and Innovent’s NDA for Fruquintinib Plus Sintilimab with Priority Review to Treat Endometrial Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
